The Prognostic Model Based on Tumor Cell Evolution Trajectory Reveals a Different Risk Group of Hepatocellular Carcinoma

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 Oct 18

PMID 34660596

Citations 6

Authors

Haoren Wang

Shizhe Yu

Qiang Cai

Duo Ma

Lingpeng Yang

Jian Zhao

Long Jiang

Xinyi Zhang

Zhiyong Yu

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide, and heterogeneity of HCC is the major barrier in improving patient outcome. To stratify HCC patients with different degrees of malignancy and provide precise treatment strategies, we reconstructed the tumor evolution trajectory with the help of scRNA-seq data and established a 30-gene prognostic model to identify the malignant state in HCC. Patients were divided into high-risk and low-risk groups. C-index and receiver operating characteristic (ROC) curve confirmed the excellent predictive value of this model. Downstream analysis revealed the underlying molecular and functional characteristics of this model, including significantly higher genomic instability and stronger proliferation/progression potential in the high-risk group. In summary, we established a novel prognostic model to overcome the barriers caused by HCC heterogeneity and provide the possibility of better clinical management for HCC patients to improve their survival outcomes.

Citing Articles

Prognostic value of preoperative systemic immune-inflammation index/albumin for patients with hepatocellular carcinoma undergoing curative resection.

Chen K, Qiu Y, Yang M, Wang T, Yang Y, Qiu H World J Gastroenterol. 2024; 30(48):5130-5151.

PMID: 39735268 PMC: 11612693. DOI: 10.3748/wjg.v30.i48.5130.

Identification and validation of a novel predictive signature based on hepatocyte-specific genes in hepatocellular carcinoma by integrated analysis of single-cell and bulk RNA sequencing.

He Y, Qi W, Xie X, Jiang H BMC Med Genomics. 2024; 17(1):103.

PMID: 38654290 PMC: 11040759. DOI: 10.1186/s12920-024-01871-1.

Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers.

Sankar K, Pearson A, Worlikar T, Perricone M, Holcomb E, Mendiratta-Lala M Transl Gastroenterol Hepatol. 2023; 8:29.

PMID: 37601739 PMC: 10432235. DOI: 10.21037/tgh-23-11.

Liver in infections: a single-cell and spatial transcriptomics perspective.

Zou J, Li J, Zhong X, Tang D, Fan X, Chen R J Biomed Sci. 2023; 30(1):53.

PMID: 37430371 PMC: 10332047. DOI: 10.1186/s12929-023-00945-z.

Unraveling the Complexity of Liver Disease One Cell at a Time.

Atif J, Thoeni C, Bader G, McGilvray I, MacParland S Semin Liver Dis. 2022; 42(3):250-270.

PMID: 36008091 PMC: 9451948. DOI: 10.1055/s-0042-1755272.

References

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Zuo Q, He J, Zhang S, Wang H, Jin G, Jin H . PPARγ Coactivator-1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ-Dependent WNT/β-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis. Hepatology. 2020; 73(2):644-660. DOI: 10.1002/hep.31280. View

Maley C, Aktipis A, Graham T, Sottoriva A, Boddy A, Janiszewska M . Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer. 2017; 17(10):605-619. PMC: 5811185. DOI: 10.1038/nrc.2017.69. View

Ni Q, Chen Z, Zheng Q, Xie D, Li J, Cheng S . Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway. Cancer Sci. 2020; 111(5):1500-1513. PMC: 7226218. DOI: 10.1111/cas.14331. View

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

Zhang Q, He Y, Luo N, Patel S, Han Y, Gao R . Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. Cell. 2019; 179(4):829-845.e20. DOI: 10.1016/j.cell.2019.10.003. View

Abou-Alfa G, Meyer T, Cheng A, El-Khoueiry A, Rimassa L, Ryoo B . Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379(1):54-63. PMC: 7523244. DOI: 10.1056/NEJMoa1717002. View

Sun X, Yu S, Zhang H, Li J, Guo W, Zhang S . A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma. Cancer Med. 2020; 9(8):2868-2878. PMC: 7163092. DOI: 10.1002/cam4.2921. View

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023-1075. PMC: 5879496. DOI: 10.1016/S0140-6736(17)33326-3. View

10.

Wang J, Wang X, Zhu G, Zhou X, Yao J, Ma X . Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma. BMC Cancer. 2021; 21(1):462. PMC: 8073913. DOI: 10.1186/s12885-021-08104-z. View

11.

Van den Berge K, Roux de Bezieux H, Street K, Saelens W, Cannoodt R, Saeys Y . Trajectory-based differential expression analysis for single-cell sequencing data. Nat Commun. 2020; 11(1):1201. PMC: 7058077. DOI: 10.1038/s41467-020-14766-3. View

12.

Zhang B, Tang B, Gao J, Li J, Kong L, Qin L . A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients. J Transl Med. 2020; 18(1):342. PMC: 7487492. DOI: 10.1186/s12967-020-02492-9. View

13.

Bidkhori G, Benfeitas R, Klevstig M, Zhang C, Nielsen J, Uhlen M . Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes. Proc Natl Acad Sci U S A. 2018; 115(50):E11874-E11883. PMC: 6294939. DOI: 10.1073/pnas.1807305115. View

14.

Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek A . MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 2015; 16:278. PMC: 4676162. DOI: 10.1186/s13059-015-0844-5. View

15.

Forero A, Li Y, Chen D, Grizzle W, Updike K, Merz N . Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer Immunol Res. 2016; 4(5):390-9. PMC: 4878913. DOI: 10.1158/2326-6066.CIR-15-0243. View

16.

Marjanovic N, Hofree M, Chan J, Canner D, Wu K, Trakala M . Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell. 2020; 38(2):229-246.e13. PMC: 7745838. DOI: 10.1016/j.ccell.2020.06.012. View

17.

Wang Y, Mashock M, Tong Z, Mu X, Chen H, Zhou X . Changing Technologies of RNA Sequencing and Their Applications in Clinical Oncology. Front Oncol. 2020; 10:447. PMC: 7160325. DOI: 10.3389/fonc.2020.00447. View

18.

Llovet J, Montal R, Sia D, Finn R . Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15(10):599-616. DOI: 10.1038/s41571-018-0073-4. View

19.

Sharma A, Seow J, Dutertre C, Pai R, Bleriot C, Mishra A . Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell. 2020; 183(2):377-394.e21. DOI: 10.1016/j.cell.2020.08.040. View

20.

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View